Clinical Trial Update: An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

View source ↗

Summary

Expanded Access Protocol update for apalutamide in non-metastatic castration-resistant prostate cancer; the protocol is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-resistant Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Status: NO_LONGER_AVAILABLE